Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Bellucci, Arianna ^a   Navarria, Laura ^a   Falarti, Elisa ^a   Zaltieri, Michela ^a   Bono, Federica ^a   Collo, Ginetta ^a   Grazia, Maria ^b   Missale, Cristina ^a   Spano, PierFranco ^a,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; DOPAMINE TRANSPORTER; COCAINE; DOPAMINE UPTAKE INHIBITOR; GLUCOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROXIMITY LIGATION ASSAY; SUBSTANTIA NIGRA; SYNAPSE; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

ALPHA-SYNUCLEIN; ANIMALS; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; GLUCOSE; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PROTEIN BINDING; SUBSTANTIA NIGRA; TRANSFECTION;

EID: 82855172161     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027959     Document Type: Article

References (60)

1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
2. Cookson MR, (2005) The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74: 29-52.
3. Tofaris GK, Spillantini MG, (2007) Physiological and pathological properties of alpha-synuclein. Cell Mol. Life Sci. 64: 2194-2201.
4. Uversky VN, (2007) Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem. 103: 17-37.
5. Kovacs GG, Milenkovic IJ, Preusser M, Budka H, (2008) Nigral burden of alpha-synuclein correlates with striatal dopamine deficit. Mov Disord. 23: 1608-1612.
6. Eriksen J, Jorgensen TN, Gether U, (2010) Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J Neurochem. 113: 27-41.
7. Eriksen J, Bjorn-Yoshimoto WE, Jorgensen TN, Newman AH, Gether U, (2010) Postendocytic sorting of constitutively internalized dopamine transporter in cell lines and dopaminergic neurons. J Biol. Chem. 285: 27289-27301.
8. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM, (1996) The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci. 16: 436-447.
9. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, et al. (1999) Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol. 409: 38-56.
10. Cragg SJ, Rice ME, (2004) DAncing past the DAT at a DA synapse. Trends Neurosci. 27: 270-277.
11. Rice ME, Cragg SJ, (2008) Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res. Rev. 58: 303-313.
12. Lee FJ, Liu F, Pristupa ZB, Niznik HB, (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J15: 916-926.
13. Wersinger C, Sidhu A, (2003) Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett. 340: 189-192.
14. Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, et al. (2008) Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation. J Neurochem. 106: 560-577.
15. Wersinger C, Prou D, Vernier P, Niznik HB, Sidhu A, (2003) Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Mol. Cell Neurosci. 24: 91-105.
16. Oaks AW, Sidhu A, (2011) Synuclein modulation of monoamine transporters. FEBS Lett. 585: 1001-1006.
17. Wersinger C, Sidhu A, (2005) Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry 44: 13612-13624.
18. Chadchankar H, Ihalainen J, Tanila H, Yavich L, (2011) Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein. Brain Res. 1382: 37-44.
19. Bolan EA, Kivell B, Jaligam V, Oz M, Jayanthi LD, et al. (2007) D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol. Pharmacol. 71: 1222-1232.
20. Zapata A, Kivell B, Han Y, Javitch JA, Bolan EA, et al. (2007) Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol. Chem. 282: 35842-35854.
21. Daws LC, Callaghan PD, Moron JA, Kahlig KM, Shippenberg TS, et al. (2002) Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem. Biophys. Res. Commun. 290: 1545-1550.
22. Little KY, Elmer LW, Zhong H, Scheys JO, Zhang L, (2002) Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol. Pharmacol. 61: 436-445.
23. Chen R, Furman CA, Gnegy ME, (2010) Dopamine transporter trafficking: rapid response on demand. Future. Neurol. 5: 123.
24. Tofaris GK, Garcia-Reitböck P, Humby T, Lambourne SL, O'Connell M, et al. (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci. 26: 3942-3950.
25. Garcia-Reitböck P, Anichtchik O, Bellucci A, Iovino M, Ballini C, et al. (2010) SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133: 2032-2044.
26. Bellucci A, Navarria L, Zaltieri M, Falarti E, Bodei S, et al. (2010) Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease. J Neurochem. 116: 588-605.
27. Specht CG, Schoepfer R, (2001) Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC. Neurosci. 2: 11-19.
28. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, et al. (2004) Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J Pathol. 165: 1643-1652.
29. Bellucci A, Luccarini I, Scali C, Prosperi C, Giovannini MG, et al. (2006) Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol. Dis. 23: 260-272.
30. Perrin RJ, Payton JE, Barnett DH, Wraight CL, Woods WS, et al. (2003) Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci. Lett. 349: 133-135.
31. Presgraves SP, Ahmed T, Borwege S, Joyce JN, (2004) Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox. Res. 5: 579-598.
32. Soderberg O, Leuchowius KJ, Gullberg M, Jarvius M, Weibrecht I, et al. (2008) Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 45: 227-232.
33. Blokzijl A, Friedman M, Ponten F, Landegren U, (2010) Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine.J Intern. Med. 268: 232-245.
34. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J Pathol. 152: 879-884.
35. Campbell BC, McLean CA, Culvenor JG, Gai WP, Blumbergs PCJ, et al. (2001) The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem. 76: 87-96.
36. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG, (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol. Chem. 278: 44405-44411.
37. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, et al. (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol. Chem. 280: 22670-22678.
38. Crowther RA, Jakes R, Spillantini MG, Goedert M, (1998) Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436: 309-312.
39. Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, et al. (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42: 8530-8540.
40. Li W, West N, Colla E, Pletnikova O, Troncoso JC, et al. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.Proc. Natl. Acad. Sci.U. S. A 102: 2162-2167.
41. Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M, (2010) Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur. J Neurosci. 32: 409-422.
42. Maiya R, Ponomarev I, Linse KD, Harris RA, Mayfield RD, (2007) Defining the dopamine transporter proteome by convergent biochemical and in silico analyses. Genes Brain Behav. 6: 97-106.
43. Roy S, Winton MJ, Black MM, Trojanowski JQ, Lee VM, (2007) Rapid and intermittent cotransport of slow component-b proteins. J Neurosci. 27: 3131-3138.
44. Mori F, Tanji K, Zhang H, Kakita A, Takahashi H, et al. (2008) Alpha-Synuclein pathology in the neostriatum in Parkinson's disease. Acta Neuropathol. 115: 453-459.
45. Jellinger KA, (2003) Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol. 106: 191-201.
46. Jellinger KA, (2005) Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA) J Neuropathol. Exp. Neurol. 64: 554.
47. Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, et al. (2003) Cerebral alterations in a MPTP-mouse model of Parkinson's disease-an immunocytochemical study. J Neural Transm. 110: 1129-1144.
48. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M, (1998) Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci.U S A 95: 6469-6473.
49. Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI, (1997) Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol. 388: 211-227.
50. Wersinger C, Banta M, Sidhu A, (2004) Comparative analyses of alpha-synuclein expression levels in rat brain tissues and transfected cells. Neurosci. Lett. 358: 95-98.
51. Fountaine TM, Wade-Martins R, (2007) RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci. Res. 85: 351-363.
52. Swant J, Goodwin JS, North A, Ali AA, Gamble-George J, et al. (2011) Alpha-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. J Biol. Chem. Oct 2011.
53. Zhou RM, Huang YX, Li XL, Chen C, Shi Q, et al. (2010) Molecular interaction of alpha-synuclein with tubulin influences on the polymerization of microtubule in vitro and structure of microtubule in cells. Mol. Biol. Rep. 37: 3183-3192.
54. Bellani S, Sousa VL, Ronzitti G, Valtorta F, Meldolesi J, et al. (2010) The regulation of synaptic function by alpha-synuclein. Commun. Integr. Biol. 3: 106-109.
55. Sousa VL, Bellani S, Giannandrea M, Yousuf M, Valtorta F, et al. (2009) Alpha-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. Mol. Biol. Cell 20: 3725-3739.
56. Furman CA, Lo CB, Stokes S, Esteban JA, Gnegy ME, (2009) Rab 11 regulates constitutive dopamine transporter trafficking and function in N2A neuroblastoma cells. Neurosci. Lett. 463: 78-81.
57. Binda F, Dipace C, Bowton E, Robertson SD, Lute BJ, et al. (2008) Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol. Pharmacol. 74: 1101-1108.
58. Lee KH, Kim MY, Kim DH, Lee YS, (2004) Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter. Neurochem. Res. 29: 1405-1409.
59. Afonso-Oramas D, Cruz-Muros I, Barroso-Chinea P, de la Rosa DA, Castro-Hernandez J, et al. (2010) The dopamine transporter is differentially regulated after dopaminergic lesion. Neurobiol. Dis. 40: 518-530.
60. Cookson MR, van der Brug M, (2008) Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp. Neurol. 209: 5-11.